Background The proto‐oncogene ROS1 encodes an intrinsic type I membrane protein of the
tyrosine kinase/insulin receptor family. ROS1 facilitates the progression of various …

Despite ROS1 fusion positive (ROS1+) NSCLC accounting approximately 1-2% of NSCLC,
there is a dizzying list of ROS1 tyrosine kinase inhibitor (TKIs) being developed in addition to …

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell
Lung Cancer (NSCLC) provide recommendations for the treatment of patients with NSCLC …

Background The role of tyrosine kinase inhibitors (TKIs) in early-stage and metastatic
oncogene-driven non–small cell lung cancer (NSCLC) is established, but it remains …

For most clinicians, even most oncologists, ROS protooncogene 1, receptor tyrosine kinase
(ROS1) fusion lung cancer remains a rare entity never encountered in actual practice …

Abstract On November 15, 2023, the US Food and Drug Administration (FDA) granted
traditional approval to repotrectinib (Augtyro®, Bristol Myers Squibb Corporation), for the …

The management of brain metastases, a potentially devastating complication of advanced
cancers, has become increasingly complex with advancements in local and systemic …

Lung cancer is a leading cause of cancer-related morbidity and mortality worldwide.
Metastases in the brain are a common hallmark of advanced stages of the disease …

Introduction Targeted therapy is used to treat lung adenocarcinoma caused by epidermal
growth factor receptor (EGFR) mutations in the tyrosine kinase domain and rare subtypes (< …

Background ROS1 fusion is a relatively low prevalence (0.6–2.0%) but targetable driver in
lung adenocarcinoma (LUAD). Robust and low-cost tests, such as immunohistochemistry …